<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179465</url>
  </required_header>
  <id_info>
    <org_study_id>2004P000078</org_study_id>
    <nct_id>NCT00179465</nct_id>
  </id_info>
  <brief_title>Treating Schizophrenia by Correcting Abnormal Brain Development</brief_title>
  <official_title>Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during
      the early course of schizophrenia can fundamentally correct the brain deficits associated
      with the disease.

      This study is funded by the National Institutes of Health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that enhancement of GABA neurotransmission during the early course of the
      illness by tiagabine (Gabitril), a GABA transporter GAT-1-specific inhibitor and a
      FDA-approved anticonvulsant, will improve both clinical symptoms and working memory in
      schizophrenia. This improvement is postulated to be the result of tiagabine-mediated
      modification of the developmental synaptic pruning of prefrontal cortical circuitry. The
      occurrence of circuitry modification after tiagabine treatment will be assessed by the
      following independent methodologic approaches: MRI morphometric analysis of prefrontal gray
      matter volume and fMRI measurements of brain activity patterns during performance of tasks
      that probe working memory.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive Functions</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Antipsychotic plus study drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antipsychotics plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the subjects will receive placebo in addition to their antipsychotic regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiagabine</intervention_name>
    <description>Up to 36 mg daily</description>
    <arm_group_label>Antipsychotic plus study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Antipsychotics plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for the diagnosis of schizophrenia, with onset of psychotic symptoms
             within the past 3 years.

          -  Currently on second-generation antipsychotics for at least 3 months.

          -  Age 18-25, otherwise healthy.

        Exclusion Criteria:

          -  Diagnosis of schizoaffective disorder.

          -  Has failed two or more clinically adequate antipsychotic trials.

          -  History of seizures or any neurologic disorders.

          -  Pregnant or nursing women.

          -  Known HIV infection.

          -  Actively suicidal.

          -  History of any substance dependence.

          -  Currently meets criteria for substance abuse/dependence.

          -  Other MRI exclusion criteria per Radiology Department protocols.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T.-U. Wilson Woo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Woo TU, Crowell AL. Targeting synapses and myelin in the prevention of schizophrenia. Schizophr Res. 2005 Mar 1;73(2-3):193-207. Review.</citation>
    <PMID>15653262</PMID>
  </reference>
  <reference>
    <citation>Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5341-6.</citation>
    <PMID>9560277</PMID>
  </reference>
  <reference>
    <citation>Woo, TUW, Spencer KS, McCarley RW. Gamma oscillations and the early course and progression of schizophrenia. Harvard Review of Psychiatry 2009.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Tsung-Ung Wilson Woo</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>fMRI</keyword>
  <keyword>Cognition</keyword>
  <keyword>Brain development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Tiagabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

